1. LDL-c reductions below 1
LDL-c reductions below 1.6 mmol/L provide additional vascular risk benefit
A meta-analysis of CTTC, IMPROVE-IT, FOURIER, and REVEAL studies
CTTC, IMPROVE-IT, FOURIER, REVEAL
IMPROVE-IT, FOURIER, REVEAL
CTTC
LDL-c lowering better
LDL-c lowering worse
LDL-c: low density lipoprotein cholesterol; CTTC: Cholesterol Treatment Trialists Collaboration; IMPROVE-IT: Improved Reduction of Outcomes: Vytorin Efficacy International Trial; FOURIER: Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk; REVEAL: Randomized Evaluation of the Effects of Anacetrapib through Lipid Modification; HR: hazard ratio; LCL: lower confidence limit; UCL: upper confidence limit
Sabatine et al. JAMA Cardiol 2018